片頭痛の世界市場レポート 2025

片頭痛の市場規模は、今後数年間で安定した成長が見込まれます。2029年にはCAGR3.3％で22億5,000万米ドルに成長します。予測期間の成長は、併用療法の採用、片頭痛のスクリーニングプログラムの増加、喫煙習慣の有病率の増加、片頭痛のライフスタイル管理の重要性の認識などに起因すると考えられます。予測期間における主な動向としては、片頭痛の革新的治療、片頭痛の標的治療の開発、片頭痛の診断と治療の進歩、片頭痛管理のためのデジタルヘルス技術などが挙げられます。

片頭痛の有病率の増加は、近い将来の片頭痛市場の拡大に拍車をかけると考えられます。片頭痛は、頭の片側が痛む激しい頭痛で、ズキズキするような強い痛みや脈打つような感覚が特徴です。片頭痛治療には、痛みの緩和、機能性の向上、発作の頻度と重症度の軽減、生産性の向上、片頭痛と闘う人々の生活の質の向上など、いくつかの利点があります。例えば、2023年1月、英国の学術誌サイトNature Reviews Neurologyが報告しているように、現在の世界の推定では、片頭痛の有病率は14～15％であり、世界全体の障害とともに生きる年数（YLDs）の4.9％に寄与しています。したがって、片頭痛の有病率の増加は、片頭痛市場の成長促進要因となっています。

片頭痛市場の成長の原動力となっているのが、ストレスの有病率の増加です。ストレスとは、個人が脅威と感じたり、圧倒されたり、効果的に対処する能力を超えていると感じたりする、困難で厳しい状況に対する生理的・心理的反応を表します。ストレスは、身体の闘争・逃走反応を引き起こし、コルチゾールやアドレナリンのようなストレスホルモンの分泌につながるため、片頭痛の引き金として作用する可能性があります。これらのホルモンは血管の急激な収縮と拡張を引き起こし、片頭痛発作に関連する血流と血管機能の変化の一因となる可能性があります。例えば、米国を拠点とする精神科医の専門組織である米国精神医学会のデータによると、2023年初頭には4人に1人以上（26％）の米国人がストレスの増加を予想しており、前年の5人に1人（20％）から増加しています。その結果、ストレスの増加が片頭痛市場の拡大に拍車をかけています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界片頭痛PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の片頭痛市場：成長率分析
• 世界の片頭痛市場の実績：規模と成長, 2019-2024
• 世界の片頭痛市場の予測：規模と成長, 2024-2029, 2034F
• 世界片頭痛総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の片頭痛市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• エピソード
• 慢性
• 世界の片頭痛市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 予防
• 中止
• 世界の片頭痛市場薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• トリプタン
• 麦角
• その他の薬物クラス

第7章 地域別・国別分析

• 世界の片頭痛市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の片頭痛市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 片頭痛市場：競合情勢
• 片頭痛市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson and Johnson Limited Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Sanofi-Aventis LLC.
• AstraZeneca PLC
• GlaxoSmithKline plc.
• Eli Lilly and Co Ltd.
• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Limited
• Perrigo Company plc
• Dr. Reddy's Laboratories Ltd.
• Apotex Inc.
• Hikma Pharmaceuticals PLC
• Cipla Limited
• Endo Pharmaceuticals Inc.
• Amneal Pharmaceuticals LLC
• Zydus Lifesciences Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 片頭痛市場2029：新たな機会を提供する国
• 片頭痛市場2029：新たな機会を提供するセグメント
• 片頭痛市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

A migraine is a neurological disorder characterized by recurrent and intense headaches, often accompanied by additional symptoms like nausea, vomiting, sensitivity to light (photophobia), and sensitivity to sound (phonophobia). These headaches are typically one-sided, pulsating, and can persist for several hours to a few days. The management of migraines involves a combination of strategies aimed at providing relief from immediate symptoms during an attack and preventing future migraine episodes.

Migraines come in two primary types are episodic and chronic. Chronic migraine is defined as experiencing headaches on at least 15 days per month for a minimum of three months, with at least 8 days each month featuring migraine-like symptoms. Treatment options include both preventive and abortive measures, involving various drug classes such as triptans, ergots, and others.

The migraine market research report is one of a series of new reports from The Business Research Company that provides migraine market statistics, including the migraine industry global market size, regional shares, competitors with a migraine market share, detailed migraine market segments, market trends and opportunities and any further data you may need to thrive in the migraine industry. This migraine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The migraine market size has grown steadily in recent years. It will grow from $1.93 billion in 2024 to $1.97 billion in 2025 at a compound annual growth rate (CAGR) of 2.2%. The growth in the historic period can be attributed to increasing prevalence of migraines, growing awareness about migraine treatment, government initiatives, increasing prevalence of alcohol consumption, shifts in lifestyle.

The migraine market size is expected to see steady growth in the next few years. It will grow to $2.25 billion in 2029 at a compound annual growth rate (CAGR) of 3.3%. The growth in the forecast period can be attributed to adoption of combination therapies, growing number of screening programs for migraines, increasing prevalence of smoking habits, awareness of the importance of lifestyle management for migraine. Major trends in the forecast period include innovative treatments for migraines, development of targeted therapies for migraines, advancements in diagnosis and treatment of migraines, digital health technologies for migraine management.

The growing prevalence of migraines is poised to fuel the expansion of the migraine market in the foreseeable future. Migraines are severe headaches typically affecting one side of the head, characterized by intense throbbing pain or a pulsing sensation. Migraine treatments offer several advantages, including pain relief, improved functionality, reduced frequency and severity of attacks, enhanced productivity, and a better quality of life for individuals grappling with migraines. For instance, in January 2023, as reported by Nature Reviews Neurology, a UK-based journal website, the current global estimate indicates a migraine prevalence of 14-15%, contributing to 4.9% of the total global years lived with disability (YLDs). Hence, the increasing prevalence of migraines is a key driver of the migraine market's growth.

The increasing prevalence of stress is the driving force behind the growth of the migraine market. Stress represents the physiological and psychological response to challenging or demanding situations that individuals perceive as threatening, overwhelming, or beyond their ability to cope with effectively. Stress can act as a trigger for migraines, as it initiates the body's fight or flight response, leading to the release of stress hormones like cortisol and adrenaline. These hormones can induce rapid constriction and dilation of blood vessels, potentially contributing to changes in blood flow and vascular function associated with migraine attacks. For example, data from the American Psychiatric Association, a US-based professional organization of psychiatrists, indicated that over one in four (26%) Americans anticipated experiencing increased stress at the beginning of 2023, up from one in five (20%) the previous year. Consequently, the rising incidence of stress is fueling the expansion of the migraine market.

The prominent companies in the migraine market are dedicated to pioneering technological solutions like migraine lens technology to gain a competitive advantage. Migraine lens technology entails the development of specialized lenses tailored to alleviate discomfort in individuals with migraines and sensitivity to light. For example, in July 2023, Zenni Optical Inc., a US-based eyewear retailer, unveiled its groundbreaking innovation, the FL-41 migraine lenses. These lenses are engineered to provide relief to individuals suffering from light sensitivity due to migraines, post-concussion recovery, and other related conditions. Moreover, these lenses filter out a specific range of light that is known to trigger eye pain, thereby reducing the risk of migraines and even offering relief during active migraine episodes.

In October 2022, Pfizer Inc., a US-based pharmaceutical and biotechnology corporation, completed the acquisition of Biohaven Pharmaceuticals Inc. for an estimated $11.6 billion. This strategic acquisition is part of Pfizer's efforts to enhance its portfolio and further its commitment to providing innovative treatment options for individuals suffering from migraines. Biohaven Pharmaceuticals Inc. is a US-based pharmaceutical company renowned for its development of migraine medications.

Major companies operating in the migraine market are Pfizer Inc., Johnson and Johnson Limited, Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi-Aventis LLC., AstraZeneca PLC, GlaxoSmithKline plc., Eli Lilly and Co Ltd., Amgen Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Perrigo Company PLC, Dr. Reddy's Laboratories Ltd., Apotex Inc., Hikma Pharmaceuticals PLC, Cipla Limited, Endo Pharmaceuticals Inc., Amneal Pharmaceuticals LLC, Zydus Lifesciences Ltd., Lupin Limited, Torrent Pharmaceuticals Ltd., Almirall S.A., Lannett Company Inc., Wockhardt Limited.

North America was the largest region in the migraine market in 2024. The regions covered in migraine report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the migraine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The migraine market consists of revenues earned by entities by providing transcranial magnetic stimulation (TMS), relaxation therapies, stress management therapies, cognitive therapies and physical therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The migraine market also includes sales of prescription and over-the-counter (OTC) drugs, medical devices and alternative therapies for the treatment of migraines. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Migraine Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on migraine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for migraine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The migraine market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Episodic; Chronic
• 2) By Treatment: Preventive; Abortive
• 3) By Drug Class: Triptans; Ergots; Other Drug Classes
• Companies Mentioned: Pfizer Inc.; Johnson and Johnson Limited; Merck & Co. Inc.; Bayer AG; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Migraine Market Characteristics

3. Migraine Market Trends And Strategies

4. Migraine Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Migraine Growth Analysis And Strategic Analysis Framework

• 5.1. Global Migraine PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Migraine Market Growth Rate Analysis
• 5.4. Global Migraine Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Migraine Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Migraine Total Addressable Market (TAM)

6. Migraine Market Segmentation

• 6.1. Global Migraine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Episodic
• Chronic
• 6.2. Global Migraine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Preventive
• Abortive
• 6.3. Global Migraine Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Triptans
• Ergots
• Other Drug Classes

7. Migraine Market Regional And Country Analysis

• 7.1. Global Migraine Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Migraine Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Migraine Market

• 8.1. Asia-Pacific Migraine Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Migraine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Migraine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Migraine Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Migraine Market

• 9.1. China Migraine Market Overview
• 9.2. China Migraine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Migraine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Migraine Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Migraine Market

• 10.1. India Migraine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Migraine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Migraine Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Migraine Market

• 11.1. Japan Migraine Market Overview
• 11.2. Japan Migraine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Migraine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Migraine Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Migraine Market

• 12.1. Australia Migraine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Migraine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Migraine Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Migraine Market

• 13.1. Indonesia Migraine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Migraine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Migraine Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Migraine Market

• 14.1. South Korea Migraine Market Overview
• 14.2. South Korea Migraine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Migraine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Migraine Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Migraine Market

• 15.1. Western Europe Migraine Market Overview
• 15.2. Western Europe Migraine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Migraine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Migraine Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Migraine Market

• 16.1. UK Migraine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Migraine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Migraine Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Migraine Market

• 17.1. Germany Migraine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Migraine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Migraine Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Migraine Market

• 18.1. France Migraine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Migraine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Migraine Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Migraine Market

• 19.1. Italy Migraine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Migraine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Migraine Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Migraine Market

• 20.1. Spain Migraine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Migraine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Migraine Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Migraine Market

• 21.1. Eastern Europe Migraine Market Overview
• 21.2. Eastern Europe Migraine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Migraine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Migraine Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Migraine Market

• 22.1. Russia Migraine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Migraine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Migraine Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Migraine Market

• 23.1. North America Migraine Market Overview
• 23.2. North America Migraine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Migraine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Migraine Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Migraine Market

• 24.1. USA Migraine Market Overview
• 24.2. USA Migraine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Migraine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Migraine Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Migraine Market

• 25.1. Canada Migraine Market Overview
• 25.2. Canada Migraine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Migraine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Migraine Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Migraine Market

• 26.1. South America Migraine Market Overview
• 26.2. South America Migraine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Migraine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Migraine Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Migraine Market

• 27.1. Brazil Migraine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Migraine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Migraine Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Migraine Market

• 28.1. Middle East Migraine Market Overview
• 28.2. Middle East Migraine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Migraine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Migraine Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Migraine Market

• 29.1. Africa Migraine Market Overview
• 29.2. Africa Migraine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Migraine Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Migraine Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Migraine Market Competitive Landscape And Company Profiles

• 30.1. Migraine Market Competitive Landscape
• 30.2. Migraine Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson and Johnson Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Migraine Market Other Major And Innovative Companies

• 31.1. Sanofi-Aventis LLC.
• 31.2. AstraZeneca PLC
• 31.3. GlaxoSmithKline plc.
• 31.4. Eli Lilly and Co Ltd.
• 31.5. Amgen Inc.
• 31.6. Teva Pharmaceutical Industries Ltd.
• 31.7. Sun Pharmaceutical Industries Limited
• 31.8. Perrigo Company plc
• 31.9. Dr. Reddy's Laboratories Ltd.
• 31.10. Apotex Inc.
• 31.11. Hikma Pharmaceuticals PLC
• 31.12. Cipla Limited
• 31.13. Endo Pharmaceuticals Inc.
• 31.14. Amneal Pharmaceuticals LLC
• 31.15. Zydus Lifesciences Ltd.

32. Global Migraine Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Migraine Market

34. Recent Developments In The Migraine Market

35. Migraine Market High Potential Countries, Segments and Strategies

• 35.1 Migraine Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Migraine Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Migraine Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer